StreetAlpha.app
Home › Stocks › SENS

Senseonics Holdings, Inc. (SENS)

Healthcare
$10.16
▼ −6.79%
LAST CLOSE · NOV 17

Senseonics makes Eversense, an implantable continuous glucose monitoring system for people with diabetes. It last closed at $10.16 on Nov 17, down 6.79% on the day. The average 12-month price target from 4 analysts is $14.50 (+42.7% from the last close), with a high of $20.00 and a low of $10.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell).

AI Auto Pilots
Is SENS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$60.0M
+104.8% vs a year ago
Net income
−$122.5M
−204.2% margin
EPS (diluted)
−$2.27
Free cash flow
−$114.0M
−190.0% margin
Valuation
Market cap
$556.6M
54.8M shares
P/E
–
No P/E while losing money
Price to sales
9.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$47.8M
At Sep 30
Debt
$54.2M
At Sep 30
Shareholder equity
$77.6M
Shares outstanding
54.8M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.4M$1.4MFY2021FY2022: $16.4M$16.4MFY2022FY2023: $22.4M$22.4MFY2023FY2024: $22.5M$22.5MFY2024FY2025: $35.3M$35.3MFY2025

From SENS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
4firms
2 Buy2 Hold0 Sell
Each firm's latest rating on SENS in the past 90 days
Average 12-month target
$14.50
▲ 42.7% upside

Based on 4 analysts who set a price target on SENS in the past 90 days. The average target is $14.50, with a high of $20.00 and a low of $10.00, compared with the last close of $10.16.

Low $10.00Avg $14.50High $20.00
Blue marker: last close $10.16
Highest target$20.00
Average target$14.50
Lowest target$10.00
Latest rating changes
MizuhoTarget raised
Nov 10Buy$18 → $20
TD CowenTarget raised
Nov 10Buy$15 → $17
StifelTarget raised
Nov 10Hold$9 → $10
BarclaysTarget raised
Nov 10Hold$10 → $11
TD CowenReiterated
Oct 27Buy$15
DateFirmActionRatingPrice target
Nov 10MizuhoTarget raisedBuy$18 → $20
Nov 10TD CowenTarget raisedBuy$15 → $17
Nov 10StifelTarget raisedHold$9 → $10
Nov 10BarclaysTarget raisedHold$10 → $11
Oct 27TD CowenReiteratedBuy$15
Loading…

Technical Analysis

SENS · as of the Nov 17 close · updated after every close
Uptrend

The stock is 10% above its 20 day and 9% above its 50 day average. It is 28% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the swing low (Sep 29) at $9.77, and the nearest resistance the swing high (Sep 24) at $10.48.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 9.9%/day
Key levels
$13.9852 week high+37.6%
$11.29Pivot R1+11.1%
$10.72Pivot+5.5%
$10.48Swing high (Sep 24)+3.1%
$10.16Last close
$9.77Swing low (Sep 29)−3.8%
$9.59Pivot S1−5.6%
$9.2150 day average−9.4%
$9.1320 day average−10.1%
$8.01100 day average−21.2%
$7.35200 day average−27.7%
$4.7952 week low−52.9%
Indicators
RSI (14)56.64Middle of its rangeNeutral
MACD0.43Above its signal lineBullish
Stochastic45.4Middle of its rangeNeutral
ADX (14)31.0Trending up
Williams %R-62.1Oversold below −80, overbought above −20Neutral
CCI (20)108.6Oversold below −100, overbought above 100Overbought
Rate of change+14.7%Change over 10 sessionsBullish
ATR (14)$1.01Typical daily range, 9.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SENS

What happened before

See how SENS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SENS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SENS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SENS in the last 90 days.

Loading…

See today’s whale options flow across the market →

SENS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲74 buying vs 47 selling
  • ▲Held by funds +5.1 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding128113+13.3%
In funds' top 1010–
Held by funds43.1%38.1%+5.1 pts
New / increased35 / 3941 / 32+1.4%
Reduced / sold out27 / 2015 / 18+42.4%
Put/call ratio0.01––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SENS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SENS is in one of them and how their past SENS trades turned out.

SENS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SENS in an article yet. Here's the latest on the wider market.

About Senseonics Holdings

Senseonics is a medical technology company that makes Eversense, an implantable continuous glucose monitoring system for people with diabetes. A small sensor is placed under the skin and works with a rechargeable transmitter and a phone app to track glucose levels for up to a year. The company sells the system to people with diabetes and to the healthcare providers who treat them, and it works with distribution partners in some markets. It is based in Germantown, Maryland.

Headquarters
Germantown, MD
Founded
1996